Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$22M
- −130.9% YoY · −38.7% QoQ
- EPS (diluted)
- −$1.54
- −79.1% YoY · −28.3% QoQ
Source: XBRL data from the PALVELLA THERAPEUTICS, INC. (PVLA) Q2 2026 10-Q on SEC EDGAR. USD.
PALVELLA THERAPEUTICS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes from the 2025 Form 10-K
- Change-in-control risk: August 3, 2026 policy accelerates unvested equity vesting after qualifying terminations
- Regulatory compliance risk: Rule 10b5-1 plan permits director sales of up to 55,000 shares
- Governance risk: policy covers vice presidents and above, including named executive officers
- Equity dilution risk: performance-based awards generally vest at target performance upon qualifying change in control
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PALVELLA THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.